Since glucocorticoids were first used to treat patients with rheumatoid arthritis in 1949, they have become the most common therapy for inflammatory disorders; however, their use is associated with major metabolic adverse events. Here, we review three 2015 reports with clinical and fundamental implications for the use of glucocorticoid therapy in rheumatology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hillier, S. G. Diamonds are forever: the cortisone legacy. J. Endocrinol. 195, 1–6 (2007).
Ruiz-Arruza, I. et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 53, 1470–1476 (2014).
Thamer, M., Hernan, M. A., Zhang, Y., Cotter, D. & Petri, M. Prednisone, lupus activity, and permanent organ damage. J. Rheumatol. 36, 560–564 (2009).
Chen, S. Y. et al. Glucocorticoid use in patients with systemic lupus erythematosus: association between dose and health care utilization and costs. Arthritis Care Res. (Hoboken) 67, 1086–1094 (2015).
Beaulieu, E. & Morand, E. F. Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 340–348 (2011).
Jones, S. A. et al. GILZ regulates TH17 responses and restrains IL-17-mediated skin inflammation. J. Autoimmun. 61, 73–80 (2015).
Bruscoli, S. et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B cell survival and results in B cell lymphocytosis in mice. Blood 126, 1790–1801 (2015).
Jones, S. A. et al. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2015-207744 (2015).
Jones, S. A., Sutton, C. E., Cua, D. & Mills, K. H. Therapeutic potential of targeting IL-17. Nat. Immunol. 13, 1022–1025 (2012).
Schewitz-Bowers, L. P. et al. Glucocorticoid-resistant TH17 cells are selectively attenuated by cyclosporine A. Proc. Natl Acad. Sci. USA 112, 4080–4085 (2015).
Acknowledgements
The authors wish to thank the Lupus Research Institute, the National Health and Medical Research Council of Australia and the Ulysses Club Arthritis Research Fund for funding their work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Jones, S., Morand, E. New answers to old problems. Nat Rev Rheumatol 12, 73–74 (2016). https://doi.org/10.1038/nrrheum.2015.176
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.176
This article is cited by
-
Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer
Reviews in Endocrine and Metabolic Disorders (2016)
